Rapamycin for Healthy Aging: Results from the TRIAD Canine Longevity Trial
Randomized, placebo-controlled trial in 586 companion dogs demonstrates modest but significant improvement in cardiac function parameters.
Editorial analyses, new database additions, and research updates from the TELOGENIS editorial team. This section is currently in development. Articles below are representative of the planned editorial format.
Randomized, placebo-controlled trial in 586 companion dogs demonstrates modest but significant improvement in cardiac function parameters.
Editorial analysis examining reproducibility concerns in high-profile NAD+ precursor supplementation studies.
Interim results from the CLEARANCE trial evaluating dasatinib + quercetin in participants with diabetic nephropathy.
Large cohort analysis (n=8,400) reveals a non-linear dose-response curve with diminishing returns above 150 min/week.
Updated protocol and power analysis for the first large-scale geroprotective trial using an FDA-approved drug.
Mechanistic review of ALT pathway activation in tumor microenvironments with high inflammatory signaling.